Lunai Bioworks Inc. (LNAI) — 8-K Filings

8-K Filings (42)

• 8-K Filing — Apr 28, 2026
• Lunai Bioworks Enters Material Definitive Agreement — Dec 3, 2025 Risk: medium
  Lunai Bioworks, Inc. (formerly RenovaRo Inc.) entered into a material definitive agreement on December 2, 2025. The company, incorporated in Delaware, is in the
• 8-K Filing — Nov 25, 2025
• Lunai Bioworks Faces Delisting Notice — Nov 6, 2025 Risk: high
  Lunai Bioworks Inc. filed an 8-K on November 6, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The earliest event reporte
• 8-K Filing — Nov 3, 2025
• Lunai Bioworks Faces Delisting Notice — Oct 30, 2025 Risk: high
  Lunai Bioworks, Inc. filed an 8-K on October 30, 2025, reporting a notice of delisting or failure to meet continued listing standards as of October 27, 2025. Th
• Lunai Bioworks Faces Delisting Concerns — Oct 16, 2025 Risk: high
  Lunai Bioworks, Inc. filed an 8-K on October 15, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, formerly kno
• Lunai Bioworks Files 8-K on Security Holder Rights — Sep 24, 2025 Risk: medium
  On September 18, 2025, Lunai Bioworks, Inc. filed an 8-K report detailing material modifications to security holder rights and amendments to its articles of inc
• Lunai Bioworks Files 8-K on Impairments — Sep 5, 2025 Risk: medium
  On September 2, 2025, Lunai Bioworks Inc. filed an 8-K report disclosing material impairments and other events. The company, formerly known as RenovaRx Inc. and
• Renovaro Inc. Files 8-K with Corporate Updates — Aug 26, 2025 Risk: low
  Renovaro Inc. filed an 8-K on August 26, 2025, reporting amendments to its articles of incorporation or bylaws and filing financial statements and exhibits. The
• Renovaro Inc. Faces Delisting Concerns — Aug 6, 2025 Risk: high
  Renovaro Inc. filed an 8-K on August 6, 2025, to report its notice of delisting or failure to satisfy a continued listing rule. The company was formerly known a
• Renovaro Inc. Reports Board and Officer Changes — Jul 25, 2025 Risk: medium
  Renovaro Inc. filed an 8-K on July 25, 2025, reporting changes related to its board of directors and officers, including the election of new directors and poten
• Renovaro Inc. Faces Delisting Notice — Jul 14, 2025 Risk: high
  Renovaro Inc. filed an 8-K on July 14, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company, formerly known as Enoc
• RenovarO Inc. Files 8-K on Material Agreement & Equity Sales — Jul 9, 2025 Risk: medium
  On July 9, 2025, RenovarO Inc. filed an 8-K detailing a material definitive agreement and unregistered sales of equity securities. The filing also included Regu
• Renovaro Inc. Appoints New Director, CMO, and CEO Compensation Update — Jun 5, 2025 Risk: medium
  Renovaro Inc. announced on May 30, 2025, changes in its board of directors and executive compensation. Specifically, the company elected Dr. Steven A. N. De Jon
• Renovaro Inc. Faces Delisting Concerns — Apr 18, 2025 Risk: high
  Renovaro Inc. filed an 8-K on April 18, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The filing indicates potential iss
• RenovaRo Inc. Files 8-K on Equity Sales — Apr 10, 2025 Risk: medium
  On April 8, 2025, RenovaRo Inc. filed an 8-K report detailing unregistered sales of equity securities and other events. The company, formerly known as Enochian
• RenovaRo Inc. Enters Material Definitive Agreement — Mar 6, 2025 Risk: medium
  On February 28, 2025, RenovaRo Inc. entered into a material definitive agreement. The filing also includes financial statements and exhibits related to this agr
• Renovaro Inc. Files 8-K: Material Agreement & Equity Sales — Feb 28, 2025 Risk: medium
  Renovaro Inc. entered into a Material Definitive Agreement on February 26, 2025. The company also disclosed unregistered sales of equity securities and provided
• Renovaro Inc. Withdraws Prior Financial Statements — Feb 19, 2025 Risk: high
  Renovaro Inc. announced on February 18, 2025, that it will not rely on previously issued financial statements. This decision impacts financial reporting and pot
• Renovaro Inc. Appoints New Director and CMO, Adjusts CEO Compensation — Feb 10, 2025 Risk: medium
  Renovaro Inc. announced on February 4, 2025, a change in its board of directors and executive compensation arrangements. Specifically, the company elected Dr. J
• Renovaro Inc. Appoints CSO, Elects Director — Jan 13, 2025 Risk: medium
  Renovaro Inc. announced on January 6, 2025, the appointment of Dr. Marc Feldmann as Chief Scientific Officer and the election of Dr. Kuldip Dave to its Board of
• RenovaRo Inc. Signs Material Definitive Agreement — Jan 7, 2025 Risk: medium
  On January 1, 2025, RenovaRo Inc. entered into a material definitive agreement. The company, formerly known as Enochian Biosciences Inc. and Renovaro Bioscience
• Renovaro Inc. Reports Director and Officer Changes — Jan 6, 2025 Risk: medium
  Renovaro Inc. filed an 8-K on January 6, 2025, reporting changes effective December 30, 2024. The filing details the departure of directors or certain officers,
• Renovaro Inc. Reports Board Changes and Compensation Updates — Nov 21, 2024 Risk: medium
  Renovaro Inc. announced on November 15, 2024, a change in its board of directors and executive compensation arrangements. The filing details the departure of ce
• Renovaro Inc. Files 8-K on Officer/Director Changes — Nov 8, 2024 Risk: medium
  Renovaro Inc. filed an 8-K on November 8, 2024, reporting events as of November 4, 2024. The filing pertains to the departure of directors or certain officers,
• Renovaro Inc. Faces Delisting Concerns — Oct 16, 2024 Risk: high
  Renovaro Inc. filed an 8-K on October 16, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, and a transfer of li
• Renovaro Inc. Faces Delisting Concerns — Sep 17, 2024 Risk: high
  Renovaro Inc. filed an 8-K on September 17, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filing indicat
• RenovaRo Inc. Changes Fiscal Year End — Sep 11, 2024 Risk: low
  On September 11, 2024, RenovaRo Inc. filed an 8-K report. The filing indicates a change in the company's fiscal year end from June 30 to December 31. This chang
• Renovaro Inc. Restates Financials Due to Equity Transaction Review — Aug 19, 2024 Risk: medium
  Renovaro Inc. announced on August 14, 2024, that it will not rely on previously issued financial statements for the fiscal year ended June 30, 2024, and interim
• Renovaro Inc. Appoints New Director — Jul 3, 2024 Risk: low
  Renovaro Inc. announced on June 27, 2024, a change in its board of directors. Dr. Jonathan L. Cohen has been appointed as a new director, effective immediately.
• Renovaro Inc. Files 8-K: Material Agreement & Equity Sales — Jun 21, 2024 Risk: medium
  Renovaro Inc. announced on June 14, 2024, that it entered into a Material Definitive Agreement. The company also reported on unregistered sales of equity securi
• RenovaRo Inc. Files 8-K Report — May 24, 2024 Risk: low
  On May 24, 2024, RenovaRo Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." The company, formerly
• Renovaro Inc. to Acquire Biotech Firm — Apr 30, 2024 Risk: medium
  Renovaro Inc. announced on April 30, 2024, that it has entered into a binding term sheet for the acquisition of a biotechnology company. The acquisition is expe
• RenovarO Inc. Files 8-K: Other Events & Financials — Apr 25, 2024 Risk: low
  On April 24, 2024, RenovarO Inc. filed an 8-K report detailing "Other Events" and "Financial Statements and Exhibits." The company, formerly known as Enochian B
• Renovaro Inc. Appoints CSO, Elects Director — Mar 13, 2024 Risk: medium
  Renovaro Inc. announced on March 11, 2024, the appointment of Dr. Marc Feldmann as Chief Scientific Officer and the election of Dr. Alan Lewis to its Board of D
• Renovaro Inc. Terminates Material Definitive Agreement — Mar 7, 2024 Risk: medium
  Renovaro Inc. announced on March 1, 2024, the termination of a material definitive agreement. The filing does not specify the counterparty or the nature of the
• Renovaro Inc. Director Resigns, Officer Compensation Details — Mar 5, 2024 Risk: low
  Renovaro Inc. announced on February 28, 2024, a change in its board of directors. Specifically, Dr. Jonathan Roth, a director, resigned from his position. The c
• Renovaro Inc. 8-K: Name History and Corporate Details Update — Feb 16, 2024 Risk: low
  Renovaro Inc. filed an 8-K on February 16, 2024, under the 'Other Events' item. The filing indicates a change in the company's name history, with previous names
• Renovaro Biosciences to Quadruple Authorized Shares to 500M — Feb 7, 2024
  Renovaro Biosciences Inc. filed an 8-K on February 7, 2024, reporting that on February 1, 2024, its Board of Directors approved an amendment to the company's Ce
• Renovaro Biosciences Updates Contact Info, Confirms Name — Jan 25, 2024
  Renovaro Biosciences Inc. filed an 8-K on January 25, 2024, primarily to update its contact information, specifically changing its business phone number to +1 (
• Renovaro Biosciences Updates Business Address & Phone on Jan 16 — Jan 16, 2024
  Renovaro Biosciences Inc. filed an 8-K on January 16, 2024, to update its business address to 2080 Century Park East, Suite 906, Los Angeles, CA 90067, and its

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX